Panitumumab outcome by tumour location analysis
Conclusions ‒ predictive
•
Boeckx N, et al. Ann Oncol 2016;27(Suppl 6):abstract 89P (and poster).
In left-sided primary tumours, panitumumab + chemotherapy
was associated with better outcomes than chemotherapy ±
bevacizumab
In right-sided primary tumours, there were indications that a
subgroup of patients benefited from panitumumab therapy
However, the optimal treatment option can not be concluded due to low
patient numbers and small absolute differences between treatment arms
Further investigation on biomarkers is warranted
